Integrin ligands and uses thereof
Synthetic αvβ6 integrin ligands of Formula I having serum stability and affinity for integrin αvβ6, which is a receptor expressed in a variety of cell types, are described. The described ligands are useful for delivering cargo molecules, such as RNAi agents or other oligonucleotide-based compounds, to cells that express integrin αvβ6, and thereby facilitating the uptake of the cargo molecules into these cells. Compositions that include αvβ6 integrin ligands and methods of use are also described.
1. An αvβ6 integrin ligand having the structure:
or a pharmaceutically acceptable salt thereof, wherein X comprises a cargo molecule.
2. The αvβ6 integrin ligand of claim 1 , wherein the αvβ6 integrin ligand comprises a structure selected from the group consisting of:
or a pharmaceutically acceptable salt thereof, wherein indicates the point of connection to a moiety comprising a cargo molecule.
3. The αvβ6 integrin ligand of claim 1 , wherein the cargo molecule is an active pharmaceutical ingredient or a prodrug.
4. The αvβ6 integrin ligand of claim 1 , wherein the cargo molecule comprises a natural or modified nucleic acid oligonucleotide.
5. The αvβ6 integrin ligand of claim 1 , wherein the cargo molecule comprises an RNAi agent.
6. The αvβ6 integrin ligand of claim 1 , further comprising a polyethylene glycol linker having 2-20 ethylene oxide units.
7. A structure comprising the αvβ6 integrin ligand of claim 1 , a linking group, and a scaffold, wherein the structure is bound to the cargo molecule.
8. The structure of claim 7 , wherein the structure comprises the αvβ6 integrin ligand in monodentate form.
9. The structure of claim 7 , wherein the structure comprises the αvβ6 integrin ligand in bidentate form.
10. The structure of claim 7 , wherein the structure comprises the αvβ6 integrin ligand in tridentate form.
11. The structure of claim 7 , wherein the structure comprises the αvβ6 integrin ligand in tetradentate form.
12. The structure of claim 7 , wherein the structure has the formula:
(Structure 701c), and wherein represents an RNAi agent.
13. A composition comprising the αvβ6 integrin ligand of claim 1 , and a pharmaceutically acceptable excipient.
14. The composition of claim 13 , wherein the αvβ6 integrin ligand is conjugated to an oligonucleotide-based compound that is capable of inhibiting the expression of a target gene in an epithelial cell.
15. The composition of claim 13 , wherein the αvβ6 integrin ligand is conjugated to an RNAi agent that is capable of inhibiting the expression of a target gene in an epithelial cell.
16. The composition of claim 13 , wherein the αvβ6 integrin ligand is conjugated to an RNAi agent that is capable of inhibiting the expression of a target gene in a bronchiolar epithelial cell.
17. A method of delivering one or more cargo molecules to a cell, the method comprising administering to the cell an αvβ6 integrin ligand of claim 1 .
18. A method of delivering one or more cargo molecules to a cell or tissue of a subject in vivo, the method comprising administering to the subject a composition of claim 13 .
19. The method of claim 18 , wherein the cell is selected from the group consisting of: type I and II alveolar epithelial cell, goblet cell, secretory epithelial cell, ciliated epithelial cell, corneal and conjunctival epithelial cell, dermal epithelial cell, cholangiocyte, enterocyte, ductal epithelial cell, glandular epithelial cell, and epithelial tumors (carcinomas).
20. The method of claim 18 , wherein the one or more cargo molecules comprises an oligonucleotide-based compound.
21. The method of claim 20 , wherein the oligonucleotide-based compound is an RNAi agent.
22. A method of inhibiting the expression of a target gene in a cell in vivo, the method comprising administering to the subject an effective amount of a composition that includes an oligonucleotide-based compound conjugated to an αvβ6 integrin ligand of claim claim 1 .
23. The method of claim 22 , wherein the cell is selected from the group consisting of: type I and II alveolar epithelial cell, goblet cell, secretory epithelial cell, ciliated epithelial cell, corneal and conjunctival epithelial cell, dermal epithelial cell, cholangiocyte, enterocyte, ductal epithelial cell, glandular epithelial cell, and epithelial tumors (carcinomas).
24. The method of claim 22 wherein the oligonucleotide-based compound is an RNAi agent.